Floatz logo

ROPIVACAINE

Chronic Low Back Pain

Johns Hopkins UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

5 Active assets in the Chronic Low Back Pain cohort.

Asset / SponsorPhaseRating
DICLOFENAC
Organon and Co
Phase 4BB
Etoricoxib
Organon and Co
Phase 4BB
Sra-333
Wake Forest University
Phase 4B
Tapentadol
Janssen Scientific Affairs, LLC
Phase 4B
Dfn-15
Endo USA Inc., a Keenova Therapeutics Company
Phase 4B

View all 15 →

Same molecule, other indications

ROPIVACAINE is also rated in:

post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →
Knee Pain ChronicDormant
BBB
Indicative ·
76 / 100
View asset →
osteoarthritis, hipDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →